查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1836808

阵发性夜间血尿症治疗市场（依治疗层级、给药频率、通路、最终用户、给药途径、治疗线和剂量强度）－全球预测 2025-2032

Paroxysmal Nocturnal Hemoglobinuria Treatment Market by Treatment Class, Administration Frequency, Distribution Channel, End User, Route of Administration, Line of Therapy, Dosage Strength - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

阵发性夜间血尿症治疗市场预计到 2032 年将成长至 81.8 亿美元，复合年增长率为 11.19%。

主要市场统计数据
基准年2024年 34.9亿美元
预计2025年 38.9亿美元
预测年份：2032年 81.8亿美元
复合年增长率（%） 11.19%

阵发性夜间血尿症的临床和策略背景以及相关人员优先考虑综合治疗途径的原因

阵发性夜间血尿症是一种罕见的后天性血液疾病，对临床、支付者和患者群体的诊断和治疗构成持续挑战。其病理生理机制由补体介导的血管内溶血和骨髓功能障碍驱动，导致其治疗需求复杂，且超出了急性治疗的范围。患者通常承受长期输血依赖、血栓形成风险和进行性性器官损害的负担，这些因素综合作用，需要涵盖专科中心、社区医院和居家照护的一体化治疗路径。

临床医生和商业相关人员必须在长期疾病改善的潜力与即时临床效益之间取得平衡，而支付方和医疗保健系统也日益要求现实世界证据能够证明疗效持久且具有成本效益。治疗方法决策不仅取决于疗效，还取决于给药频率、给药途径以及慢性治疗管理的后勤安排。因此，治疗和服务的策略规划必须兼顾临床终点和在不同医疗环境中的营运可行性。

本引言重点阐述了科学创新、医疗服务模式和医疗资源取得限制之间的相互作用，为后续分析奠定了框架。它也为探索不断变化的治疗模式和外部政策力量如何共同作用，重新定义製造商、医疗服务提供者和患者的优先事项奠定了基础。本引言旨在为决策者提供清晰的基准，以便他们可以解读下一节中提出的变革趋势和战术性建议。

最近的科学突破、付款人期望的变化以及以患者为中心的护理模式如何重塑罕见血液疾病的治疗模式

阵发性夜间血尿症）的治疗格局正被多重相互依存的变革再形成，这些变革既改变了临床应用，也改变了市场策略的考量。补体生物学的进展和标靶抑制剂的成熟正在扩大治疗选择的范围，而基因改造方法的同步创新则有望实现持续的造血功能矫正。这些科学进步伴随着服务模式的创新，这些模式优先考虑门诊管理和居家管理，从而影响了付款人合约和管道动态。

同时，付款人的期望正在从偶尔使用高成本输液转变为基于绩效的安排和与结果挂钩的报销。付款人不仅关注临床有效性，还关注治疗方法降低总医疗成本、患者报告结果以及血栓症和输血依赖等后续併发症的能力。这种转变促使製造商需要透过临床试验和强有力的真实世界证据计画来证明其长期效益。

患者的声音正变得越来越有影响力，促使製造商和医疗保健提供者优化治疗便利性，减轻输液负担，并透过远端医疗追踪和居家输液框架扩大可及性。这些变革性动态共同要求相关人员采取整合的商业和临床策略，将治疗方法差异化与切实可行的交付解决方案以及以支付方为导向的证据产生相结合。

评估 2025 年美国关税对供应链、定价权以及患者获得复杂生技药品和先进疗法的累积影响

2025年美国加征关税将对支持复杂生技药品以及先进细胞和基因疗法的整个供应链产生连锁反应，影响定价、生产在地化以及病患用药管道。更高的进口关税将增加关键原料、专用试剂和生物製药，而这些产品通常透过全球供应链生产。这些成本的上升将迫使製造商重新评估定价策略，吸收利润率的下降，或重新配置生产地点以降低风险。

作为应对，一些开发商可能会加快对国内製造产能的投资，或寻求关键零件的近岸外包，以降低关税风险并缩短物流前置作业时间。虽然此类策略转变需要资金和时间，但它们有可能提高供应弹性和对需求波动的应对力。同时，经销商和专业药局在应对不同产品类型和采购管道的关税影响时，面临日益复杂的营运。

对于病患和医疗保健提供者而言，关税带来的累积成本压力可能表现为更严格的支付方涵盖政策、更严格的医疗服务使用管理，或在福利设计允许的情况下增加自付费用。在扩大覆盖范围之前，支付方可能需要更有力的比较有效性证据，并证明下游资源使用减少。因此，製造商应主动与支付者进行价值沟通，以具体阐述临床效用、概述降低附带成本的照护途径，并提案分散风险的风险分担结构。同时，在关税波动的情况下，制定生产和供应连续性的应急计划（包括双重筹资策略和区域库存缓衝）对于维持患者获得药物至关重要。

整合基于证据的细分洞察，将治疗层级、给药频率、分销管道和患者环境与商业策略联繫起来

对阵发性夜间血尿症）治疗格局进行详细细分，揭示了差异化的机会和限制因素，有助于确定策略优先顺序。按治疗层级，市场包括补体抑制剂，包括Eculizumab和Ravulizumab等成熟的单株抗体疗法；利用慢病毒平台的基因疗法，例如LentiGlobin疗法；以及支持性治疗，包括输血和铁螯合疗法。补体抑制剂可对血管内溶血进行可预测的控制，基因疗法有望实现持久的缓解疾病，而支持性治疗对于症状管理和併发症缓解至关重要。

给药频率是决定病患便利性和医疗系统资源利用率的关键因素。与每2週给药一次的疗法相比，每8週给药一次的方案在物流具有明显的优势。分销管道塑造了非处方药的可及性和患者体验。医院药局环境提供一体化专科护理，线上药局通路提供宅配和便利服务，零售药局提供地理覆盖和快速配药服务。终端用户的动态进一步影响了采用模式。居家医疗环境支援分散管理，并可降低设施成本。医院仍然是发起和管理复杂病例的支点，而专科诊所则是提供高级护理的卓越中心。

给药途径区分了临床工作流程，静脉注射需要输液设施，而皮下给药则更适合门诊病人或自行给药。高剂量、低剂量和标准剂量等剂量强度类别会影响安全性监测、生产复杂性和报销谈判。整合这些细分层面，可以从多维度洞察治疗和商业性投资在何处能够带来最大的策略回报。

区域策略视角，详述全球主要市场在临床采用模式、法规环境和取得途径的差异

区域动态显着影响阵发性夜间血尿症的临床应用、法规环境和患者治疗可近性，因此需要製定兼顾不同支付方环境和医疗服务提供基础设施的区域策略。在美洲，高度专业化的医疗网络、高成本生物製药报销框架以及不断扩展的家庭输液能力，有利于补体抑制剂和新型基因修饰疗法的推广，但支付方的审查仍然十分严格。在欧洲、中东和非洲地区，多种因素可能阻碍复杂治疗方法的快速普及，包括部分欧洲市场的严格监管、各国报销计画的差异以及中东和非洲部分地区有限的基础设施挑战。

亚太地区正经历着患者需求的快速成长和多样化的管理体制。一些国家正在加快核准创新治疗方法，而另一些国家则需要更多时间进行本地证据累积和价格谈判。在每个地区，医院容量、专业输液中心的普及程度以及专业药房网路的成熟度存在差异，导致通路策略和病患支援计画的设计也存在差异。因此，相关人员必须采取多层次的区域性方法，将全球临床证据与基于本地的卫生经济模型、有针对性的相关人员参与计画以及灵活的分销模式相结合，以确保先进治疗方案的采用和永续性。

领先的开发商、创新者和服务供应商的竞争定位和策略倡议正在影响治疗方法选择和商业化策略

阵发性夜间血尿症）治疗领域的竞争态势，由成熟的生物製药公司、敏捷的临床阶段创新公司以及支持分销和居家给药的服务供应商共同塑造。现有的补体抑制剂开发商已建立持久的临床产品组合，且为医疗机构所熟知，这为新参与企业设定了较高的进入门槛，除非他们能够提供有意义的差异化优势，例如延长给药间隔、提高安全性或简化给药方式。同时，致力于基因治疗策略的临床阶段公司正在透过提供持久疗效的潜力来改变长期治疗的格局，从而减轻终身治疗负担。

服务供应商、专业药房和综合护理网络同样重要，因为它们运作的交付模式会影响患者的依从性和实际疗效。製造商与服务供应商之间的伙伴关係对于产品上市计画日益重要，因为复杂的治疗方法需要协调一致的培训、病患支援和报销流程。对于评估自身定位的公司而言，重要的是将临床差异化与实际交付模式和以付款人为中心的证据生成相结合，同时保持灵活的联盟构建，以加速市场进入和规模发展。

为产业领导者提供有针对性的、切实可行的策略行动，以加速采用、优化交付模式并在不断变化的政策环境中保护访问

行业领导者应采取一系列有针对性、可操作的措施，将科学进步转化为持续的患者获益和永续的商业性回报。首先，应优先产生能够引起付款方共鸣的证据，为此应投资于纵向、真实世界的数据集，以量化输血成瘾、血栓事件和整体医疗保健利用率的降低。这应与前瞻性註册设计和结果指标相结合，以捕捉患者报告的益处和生活品质的改善。

其次，我们将透过营运优势（例如延长给药间隔，并在临床适用的情况下进行皮下或居家给药）来优化产品差异化，以减轻护理负担并提高依从性。第三，我们将透过实施关键投入的双重采购、评估区域生产方案以及与专业药房合作来简化居家管理和患者支持，从而增强分销韧性。第四，我们将积极与付款人合作，采用创新的合约方式，例如基于结果的协议，以共担风险并体现价值一致性。第五，我们将开发模组化上市方案，该方案可在美洲、欧洲、中东和非洲以及亚太地区进行在地化，同时考虑到监管特殊性和通路成熟度。最后，我们将投资临床医生和病患教育，以促进早期诊断和及时选择治疗方法，确保新疗法惠及最有可能受益的患者，同时最大限度地减少不当使用。

一种透明的调查方法，将数据三角测量、专家参与和分析框架结合在一起，以产生可靠、可操作的见解

本分析的基础研究将结构化的次要研究与一手定性研究结合，以确保洞察的广度和深度。二级资讯来源包括同行评审的临床文献、监管资讯以及公开的产品标籤和指导文件，这些资料相结合，建立了坚实的临床和监管基准。一手研究包括对血液科医生、专科药房负责人、付款方医疗主任和患者权益代表的深入访谈，以了解他们对治疗偏好、获取障碍和证据期望的细微观点。

分析方法包括跨细分映射，以揭示跨治疗层级、给药频率、分销管道、最终用户环境、给药途径、治疗线和剂量强度的交叉洞察。情境分析评估了与关税相关的供应中断以及在不断变化的报销条件下经过压力测试的定价和可及性策略的潜在营运和商业性后果。自始至终使用证据三角测量来协调对照试验疗效与现实世界疗效之间的差异，并承认由于纵向数据有限，基因疗法等新型治疗方法存在局限性。调查方法强调透明度和可重复性，使相关人员能够理解策略建议背后的假设。

综合结论，强调关键曲折点、相关人员的责任以及迈向持久的以患者为中心的护理模式的蓝图

最后，阵发性夜间血尿症）的治疗现状正处于曲折点，科学创新与营运和政策挑战交织在一起。补体抑制剂持续提供有效的临床控制，基因改造方法有望为某些患者族群带来长期改善。然而，充分发挥这些进展的潜力，有赖于製造商、医疗保健提供者、付款人和服务合作伙伴的共同努力，以协调证据生成、交付模式和可及性策略。

拥有便捷的行政管理、强大的供应链弹性以及与付款方合作积极主动地获取证据的利益相关人员，最有能力将临床潜力转化为持续的患者获益。居家照护支援、以结果为导向的报销机制以及不断发展的当地法规的融合，为创建差异化项目创造了机会，从而降低护理总成本，同时改善患者的生活品质。最终，改善疗效的蓝图将严谨的科学、务实的营运设计和付款方的协作参与相结合，确保治疗进展转化为阵发性夜间血尿症患者的可衡量改善。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

  • 针对伴有残留溶血的 PNH 患者上游补体活化的补体 C3 抑制剂的出现
  • 扩大皮下注射Ravulizumab製剂的应用，以提高患者的便利性和依从性
  • 开发一种新型基因治疗方法，持续矫正 PNH 患者骨髓干细胞中的 PIGA 基因
  • 透过高灵敏度的 LDH 和血红蛋白监测扩展生物标记主导的个人化治疗策略
  • 来自生物相似药 C5 抑制剂的竞争日益激烈，威胁现有的单株抗体定价模式
  • 整合针对C5和C3的多功能双特异性抗体以增强补体调节
  • 人们对健康经济结果研究的兴趣日益浓厚，这些研究证明了早期 PNH 介入策略的长期成本节约
  • 小分子因子 D 抑制剂作为 PNH 患者口服补体抑制剂替代品的研究进展

第六章：2025年美国关税的累积影响

第七章：人工智慧的累积影响，2025年

第八章阵发性夜间血尿症治疗市场（依治疗层级）

  • 补体抑制剂
    • Eculizumab
    • Ravulizumab
  • 基因治疗
    • 慢球蛋白基因治疗
  • 支持性护理
    • 输血
    • 铁螯合疗法

第九章阵发性夜间血尿症治疗市场（以剂量频率）

  • 每 8 週
  • 每两週

第 10 章阵发性夜间血尿症治疗市场（按通路）

  • 医院药房
  • 网路药局
  • 零售药局

第 11 章阵发性夜间血尿症治疗市场（依最终使用者）

  • 居家照护环境
  • 医院
  • 专科诊所

第12章阵发性夜间血尿症治疗市场（依给药途径）

  • 静脉注射
  • 皮下给药

第13章阵发性夜间血尿症治疗市场治疗线

  • 第一行
  • 第二行
  • 第三行

第 14 章阵发性夜间血尿症治疗市场（按剂量强度）

  • 高剂量
  • 低剂量
  • 标准剂量

第15章阵发性夜间血尿症治疗市场（按地区）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第16章阵发性夜间血尿症治疗市场（按类别）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第17章阵发性夜间血尿症治疗市场（按国家）

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十八章竞争格局

  • 2024年市占率分析
  • 2024年FPNV定位矩阵
  • 竞争分析
    • AstraZeneca plc
    • Apellis Pharmaceuticals, Inc.
    • Swedish Orphan Biovitrum AB
    • Novartis AG
    • Genentech, Inc.
    • Amgen Inc.
    • F. Hoffmann-La Roche Ltd.
Product Code: MRR-036C5CF3B54F

The Paroxysmal Nocturnal Hemoglobinuria Treatment Market is projected to grow by USD 8.18 billion at a CAGR of 11.19% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 3.49 billion
Estimated Year [2025] USD 3.89 billion
Forecast Year [2032] USD 8.18 billion
CAGR (%) 11.19%

Framing the clinical and strategic context of paroxysmal nocturnal hemoglobinuria and why stakeholders must prioritize integrated therapeutic pathways

Paroxysmal nocturnal hemoglobinuria is a rare, acquired hematologic disorder that poses persistent diagnostic and therapeutic challenges across clinical, payer, and patient communities. Its pathophysiology, driven by complement-mediated intravascular hemolysis and bone marrow dysfunction, gives rise to complex care needs that extend beyond acute treatment episodes. Patients often experience burdens that include chronic transfusion dependence, thrombotic risk, and progressive organ damage, which together mandate an integrated care pathway that spans specialty centers, community hospitals, and home-based services.

Clinicians and commercial stakeholders must balance immediate clinical benefit against long-term disease modification potential, while payers and health systems increasingly demand real-world evidence demonstrating sustained outcomes and cost-effectiveness. Treatment decisions hinge not only on efficacy but also on administration frequency, route of delivery, and the logistics of chronic therapy management. As a result, strategic planning for therapeutics and services must consider both clinical endpoints and operational feasibility in diverse care settings.

This introduction frames the subsequent analysis by underscoring the interplay between scientific innovation, care delivery models, and access constraints. It establishes the groundwork for exploring how shifting therapeutic modalities and external policy forces are converging to redefine priorities for manufacturers, providers, and patients alike. The intent is to equip decision-makers with a clear baseline from which to interpret transformational trends and tactical recommendations presented in the following sections.

How recent scientific breakthroughs, shifting payer expectations, and patient-centered care models are reshaping therapeutic paradigms for rare hematologic disorders

The landscape for treating paroxysmal nocturnal hemoglobinuria is being reshaped by multiple, interdependent shifts that together alter the calculus for clinical adoption and market strategy. Advances in complement biology and the maturation of targeted inhibitors have extended the spectrum of therapeutic options, while parallel innovations in gene-modifying approaches promise the possibility of durable hematopoietic correction. These scientific advances are being accompanied by service-model innovations that prioritize outpatient management and home-based administration, which in turn influence payer contracting and channel dynamics.

At the same time, payer expectations are evolving from episodic coverage of high-cost infusions toward performance-based arrangements and outcomes-linked reimbursement. Payers are scrutinizing not only clinical efficacy but also total cost of care, patient-reported outcomes, and the capacity for therapies to reduce downstream complications such as thrombosis and transfusion dependence. This shift compels manufacturers to demonstrate longitudinal benefit through both clinical trials and robust real-world evidence programs.

The patient voice is gaining influence, driving manufacturers and providers to optimize treatment convenience, reduce infusion burden, and expand access through telehealth-enabled follow-up and home infusion frameworks. Collectively, these transformative dynamics demand that stakeholders adopt integrated commercialization and clinical strategies that align therapeutic differentiation with pragmatic delivery solutions and payer-aligned evidence generation.

Assessing the cumulative implications of United States tariffs in 2025 on supply chains, pricing dynamics, and patient access for complex biologics and advanced therapies

The introduction of tariff measures in the United States during 2025 has produced cascading effects across the supply chains supporting complex biologics and advanced cell and gene therapies, with implications for pricing, manufacturing localization, and patient access. Increased import tariffs raise direct input costs for critical raw materials, specialized reagents, and finished biologic products that are often manufactured through global supply chains. These elevated costs pressure manufacturers to reassess pricing strategies, absorb margin erosion, or reconfigure production footprints to mitigate exposure.

In response, some developers may accelerate investments in domestic manufacturing capability or pursue near-shoring for critical components to reduce tariff risk and shorten logistical lead times. Such strategic reorientation requires capital and time but can yield supply resilience and improved responsiveness to demand variability. Meanwhile, distributors and specialty pharmacies face increased operational complexity as they navigate patchworked tariff implications across product categories and sourcing channels, which may alter channel economics and push certain therapies toward consolidated distribution models.

For patients and providers, cumulative tariff-driven cost pressures can manifest as tighter payer coverage policies, heightened utilization management, or increased out-of-pocket exposure where benefit design permits. Payers may demand stronger evidence of comparative effectiveness and demonstrable reductions in downstream resource use before extending broad coverage. Consequently, manufacturers should proactively engage payers with value dossiers that contextualize clinical benefit, demonstrate care pathways that reduce ancillary costs, and propose risk-sharing constructs that spread exposure. In parallel, contingency planning for manufacturing and supply continuity, including dual-sourcing strategies and regional inventory buffers, will be essential to maintain patient access in the face of tariff volatility.

An evidence-driven segmentation insight synthesis linking treatment class, administration frequency, distribution channel, and patient settings to commercial strategy

Deep segmentation of the paroxysmal nocturnal hemoglobinuria therapeutic landscape reveals differentiated opportunities and constraints that should inform strategic prioritization. When viewed through treatment class, the market comprises complement inhibitors, which include well-established monoclonal antibody therapies such as eculizumab and ravulizumab; gene therapies that are leveraging lentiviral platforms exemplified by LentiGlobin approaches; and supportive therapies encompassing blood transfusion and iron chelation therapy. Each class carries distinct value propositions: complement inhibitors offer predictable control of intravascular hemolysis, gene therapies promise durable disease modification, and supportive measures remain essential for symptomatic management and comorbidity mitigation.

Administration frequency is a pivotal determinant of patient convenience and health-system resource use, with regimens administered every eight weeks offering clear logistics advantages compared with therapies requiring dosing every two weeks. Distribution channels shape commercial access and patient experience, with hospital pharmacy environments providing integrated specialty care, online pharmacy channels enabling home delivery and convenience, and retail pharmacies offering geographic accessibility and rapid dispensing. End-user dynamics further nuance adoption patterns: home care settings enable decentralized administration and can reduce institutional costs; hospitals remain the fulcrum for initiation and management of complex cases; and specialty clinics act as centers of excellence for advanced therapies.

Route of administration differentiates clinical workflows, contrasting intravenous administration that requires infusion infrastructure with subcutaneous administration that favors outpatient or self-administration. Line-of-therapy considerations-spanning first line through third line-drive clinical sequencing and payer coverage thresholds, while dosage strength segments such as high dose, low dose, and standard dose influence safety monitoring, manufacturing complexity, and reimbursement negotiation. Integrating these segmentation layers yields a multidimensional view of where therapeutic and commercial investments will deliver the greatest strategic returns.

Regional strategic outlook detailing differential clinical adoption patterns, regulatory environments, and access pathways across key global markets

Regional dynamics materially influence clinical adoption, regulatory pathways, and patient access for paroxysmal nocturnal hemoglobinuria therapies, necessitating region-specific strategies that acknowledge distinct payer landscapes and care delivery infrastructures. In the Americas, advanced specialty care networks, established reimbursement frameworks for high-cost biologics, and growing home infusion capabilities create a receptive environment for both complement inhibitors and emerging gene-modifying therapies, although payer scrutiny remains rigorous. Europe, Middle East & Africa presents a heterogeneous mix of centralized regulatory oversight in some European markets, variable reimbursement timelines across countries, and limited infrastructure challenges in parts of the Middle East and Africa that can impede rapid adoption of complex therapies.

The Asia-Pacific region offers rapid patient demand growth and diverse regulatory regimes, with some countries accelerating approvals for innovative therapies while others require extended local evidence generation and pricing negotiations. Across all regions, differences in hospital capacity, prevalence of specialty infusion centers, and maturity of specialty pharmacy networks drive variations in channel strategy and patient support program design. Stakeholders must therefore adopt a layered regional approach that combines global clinical evidence with locally grounded health economic models, targeted stakeholder engagement plans, and adaptable distribution models to ensure both uptake and sustainability of advanced therapeutic options.

Competitive positioning and strategic moves by leading developers, innovators, and service providers shaping therapeutic choices and commercialization strategies

Competitive dynamics in paroxysmal nocturnal hemoglobinuria treatment are shaped by a combination of established biologic incumbents, nimble clinical-stage innovators, and service providers that enable distribution and home administration. Established complement inhibitor developers have built durable clinical portfolios and provider familiarity, creating high barriers for new entrants unless they deliver meaningful differentiation such as extended dosing intervals, improved safety profiles, or simpler administration. At the same time, clinical-stage companies pursuing gene therapy strategies are changing the long-term conversation by presenting the potential for durable responses that could reduce lifetime treatment burden.

Service providers, specialty pharmacies, and integrated care networks are equally important, as they operationalize delivery models that influence patient adherence and real-world outcomes. Partnerships across manufacturers and service providers are increasingly central to launch plans, as coordinated approaches to training, patient support, and reimbursement navigation are required for complex therapies. For companies evaluating their positioning, the key is to align clinical differentiation with pragmatic delivery models and payer-focused evidence generation, while remaining flexible to form alliances that accelerate market entry and scale.

Targeted, practical strategic actions for industry leaders to accelerate adoption, optimize delivery models, and safeguard access amid evolving policy landscapes

Industry leaders should pursue a set of targeted, actionable imperatives to translate scientific advances into durable patient benefit and sustainable commercial returns. First, prioritize evidence generation that resonates with payers by investing in longitudinal real-world datasets that quantify reductions in transfusion dependence, thrombotic events, and overall healthcare utilization. This should be paired with prospective registry designs and outcomes measures that capture patient-reported benefits and quality-of-life improvements.

Second, optimize product differentiation through operational advantages such as extending administration intervals and enabling subcutaneous or home-based delivery where clinically appropriate, thereby reducing care burden and improving adherence. Third, strengthen distribution resilience by implementing dual-sourcing for critical inputs, evaluating regional manufacturing options, and partnering with specialty pharmacies to streamline home administration and patient support. Fourth, proactively engage payers with innovative contracting approaches, including outcomes-based arrangements that share risk and demonstrate value alignment. Fifth, develop modular launch playbooks that can be localized for the Americas, Europe, Middle East & Africa, and Asia-Pacific, accounting for regulatory idiosyncrasies and channel maturity. Finally, invest in clinician and patient education to foster early diagnosis and timely therapeutic escalation, ensuring that novel therapies reach the patients most likely to benefit while minimizing inappropriate utilization.

Transparent research methodology summarizing data triangulation, expert engagement, and analytical frameworks used to produce robust actionable insights

The research underpinning this analysis combines structured secondary research with primary qualitative engagement to ensure both breadth and depth of insight. Secondary sources included peer-reviewed clinical literature, regulatory communications, and publicly available product labeling and guidance documents, which were synthesized to establish a robust clinical and regulatory baseline. Primary research comprised in-depth interviews with hematology specialists, specialty pharmacy leaders, payer medical directors, and patient advocacy representatives to capture nuanced perspectives on treatment preferences, access barriers, and evidence expectations.

Analytical methods included cross-segmentation mapping to reveal intersectional insights across treatment class, administration frequency, distribution channels, end-user settings, route of administration, line of therapy, and dosage strength. Scenario analysis was applied to evaluate the potential operational and commercial outcomes of tariff-related supply disruptions and to stress-test pricing and access strategies under variable reimbursement conditions. Triangulation of evidence was used throughout to reconcile differences between controlled-trial efficacy and real-world effectiveness, and limitations are acknowledged where emerging modalities such as gene therapies have limited longitudinal data. The methodology emphasizes transparency and reproducibility, enabling stakeholders to understand the assumptions that underlie strategic recommendations.

Concluding synthesis highlighting critical inflection points, stakeholder responsibilities, and the roadmap toward durable patient-centric care models

In closing, the paroxysmal nocturnal hemoglobinuria landscape is at an inflection point where scientific innovation intersects with operational and policy challenges. Complement inhibitors continue to provide meaningful clinical control, while gene-modifying approaches hold the promise of long-term correction for select patient populations. Yet realizing the full potential of these advances depends on coordinated efforts across manufacturers, providers, payers, and service partners to align evidence generation, delivery models, and access strategies.

Stakeholders that proactively address administration convenience, supply chain resilience, and payer-aligned evidence generation will be best positioned to convert clinical promise into sustained patient benefit. The convergence of home-care enablement, outcomes-focused reimbursement, and regional regulatory evolution creates openings for differentiated programs that reduce total cost of care while enhancing patient quality of life. Ultimately, the roadmap to improved outcomes combines rigorous science with pragmatic operational design and collaborative payer engagement, ensuring that therapeutic advances translate into measurable improvements for patients living with paroxysmal nocturnal hemoglobinuria.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Emergence of complement C3 inhibitors targeting upstream complement activation in PNH patients with residual hemolysis
  • 5.2. Increasing adoption of subcutaneous ravulizumab formulations to improve patient convenience and adherence
  • 5.3. Development of novel gene therapies aiming for sustained PIGA gene correction in PNH bone marrow stem cells
  • 5.4. Expansion of biomarker-driven personalized treatment strategies through high-sensitivity LDH and hemoglobin monitoring
  • 5.5. Rising competition from biosimilar C5 inhibitors challenging incumbent monoclonal antibody pricing models
  • 5.6. Integration of multifunctional bispecific antibodies targeting both C5 and C3 to enhance complement regulation
  • 5.7. Growing focus on health economic outcomes research demonstrating long-term cost savings of early PNH intervention strategies
  • 5.8. Advances in small molecule factor D inhibitors offering oral complement blockade alternatives for PNH patients

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Paroxysmal Nocturnal Hemoglobinuria Treatment Market, by Treatment Class

  • 8.1. Complement Inhibitors
    • 8.1.1. Eculizumab
    • 8.1.2. Ravulizumab
  • 8.2. Gene Therapies
    • 8.2.1. LentiGlobin Gene Therapy
  • 8.3. Supportive Therapies
    • 8.3.1. Blood Transfusion
    • 8.3.2. Iron Chelation Therapy

9. Paroxysmal Nocturnal Hemoglobinuria Treatment Market, by Administration Frequency

  • 9.1. Every Eight Weeks
  • 9.2. Every Two Weeks

10. Paroxysmal Nocturnal Hemoglobinuria Treatment Market, by Distribution Channel

  • 10.1. Hospital Pharmacy
  • 10.2. Online Pharmacy
  • 10.3. Retail Pharmacy

11. Paroxysmal Nocturnal Hemoglobinuria Treatment Market, by End User

  • 11.1. Home Care Settings
  • 11.2. Hospitals
  • 11.3. Specialty Clinics

12. Paroxysmal Nocturnal Hemoglobinuria Treatment Market, by Route of Administration

  • 12.1. Intravenous Administration
  • 12.2. Subcutaneous Administration

13. Paroxysmal Nocturnal Hemoglobinuria Treatment Market, by Line of Therapy

  • 13.1. First Line
  • 13.2. Second Line
  • 13.3. Third Line

14. Paroxysmal Nocturnal Hemoglobinuria Treatment Market, by Dosage Strength

  • 14.1. High Dose
  • 14.2. Low Dose
  • 14.3. Standard Dose

15. Paroxysmal Nocturnal Hemoglobinuria Treatment Market, by Region

  • 15.1. Americas
    • 15.1.1. North America
    • 15.1.2. Latin America
  • 15.2. Europe, Middle East & Africa
    • 15.2.1. Europe
    • 15.2.2. Middle East
    • 15.2.3. Africa
  • 15.3. Asia-Pacific

16. Paroxysmal Nocturnal Hemoglobinuria Treatment Market, by Group

  • 16.1. ASEAN
  • 16.2. GCC
  • 16.3. European Union
  • 16.4. BRICS
  • 16.5. G7
  • 16.6. NATO

17. Paroxysmal Nocturnal Hemoglobinuria Treatment Market, by Country

  • 17.1. United States
  • 17.2. Canada
  • 17.3. Mexico
  • 17.4. Brazil
  • 17.5. United Kingdom
  • 17.6. Germany
  • 17.7. France
  • 17.8. Russia
  • 17.9. Italy
  • 17.10. Spain
  • 17.11. China
  • 17.12. India
  • 17.13. Japan
  • 17.14. Australia
  • 17.15. South Korea

18. Competitive Landscape

  • 18.1. Market Share Analysis, 2024
  • 18.2. FPNV Positioning Matrix, 2024
  • 18.3. Competitive Analysis
    • 18.3.1. AstraZeneca plc
    • 18.3.2. Apellis Pharmaceuticals, Inc.
    • 18.3.3. Swedish Orphan Biovitrum AB
    • 18.3.4. Novartis AG
    • 18.3.5. Genentech, Inc.
    • 18.3.6. Amgen Inc.
    • 18.3.7. F. Hoffmann-La Roche Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ADMINISTRATION FREQUENCY, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ADMINISTRATION FREQUENCY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DOSAGE STRENGTH, 2024 VS 2032 (%)
  • FIGURE 15. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DOSAGE STRENGTH, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AMERICAS PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. NORTH AMERICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. LATIN AMERICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. EUROPE PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. MIDDLE EAST PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. AFRICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASIA-PACIFIC PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. ASEAN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. GCC PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. EUROPEAN UNION PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. BRICS PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. G7 PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. NATO PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 32. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 33. PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 34. PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COMPLEMENT INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COMPLEMENT INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COMPLEMENT INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COMPLEMENT INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COMPLEMENT INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COMPLEMENT INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COMPLEMENT INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COMPLEMENT INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ECULIZUMAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ECULIZUMAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ECULIZUMAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ECULIZUMAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ECULIZUMAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ECULIZUMAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY RAVULIZUMAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY RAVULIZUMAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY RAVULIZUMAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY RAVULIZUMAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY RAVULIZUMAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY RAVULIZUMAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY GENE THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY GENE THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY GENE THERAPIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY GENE THERAPIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY GENE THERAPIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY GENE THERAPIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY GENE THERAPIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY GENE THERAPIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY LENTIGLOBIN GENE THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY LENTIGLOBIN GENE THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY LENTIGLOBIN GENE THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY LENTIGLOBIN GENE THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY LENTIGLOBIN GENE THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY LENTIGLOBIN GENE THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY BLOOD TRANSFUSION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY BLOOD TRANSFUSION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY BLOOD TRANSFUSION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY BLOOD TRANSFUSION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY BLOOD TRANSFUSION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY BLOOD TRANSFUSION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY IRON CHELATION THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY IRON CHELATION THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY IRON CHELATION THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY IRON CHELATION THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY IRON CHELATION THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY IRON CHELATION THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ADMINISTRATION FREQUENCY, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ADMINISTRATION FREQUENCY, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY EVERY EIGHT WEEKS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY EVERY EIGHT WEEKS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY EVERY EIGHT WEEKS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY EVERY EIGHT WEEKS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY EVERY EIGHT WEEKS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY EVERY EIGHT WEEKS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY EVERY TWO WEEKS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY EVERY TWO WEEKS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY EVERY TWO WEEKS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY EVERY TWO WEEKS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY EVERY TWO WEEKS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY EVERY TWO WEEKS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY INTRAVENOUS ADMINISTRATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY INTRAVENOUS ADMINISTRATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY INTRAVENOUS ADMINISTRATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY INTRAVENOUS ADMINISTRATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY INTRAVENOUS ADMINISTRATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY INTRAVENOUS ADMINISTRATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SUBCUTANEOUS ADMINISTRATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SUBCUTANEOUS ADMINISTRATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SUBCUTANEOUS ADMINISTRATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SUBCUTANEOUS ADMINISTRATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SUBCUTANEOUS ADMINISTRATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SUBCUTANEOUS ADMINISTRATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY FIRST LINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY FIRST LINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY FIRST LINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SECOND LINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SECOND LINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SECOND LINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY THIRD LINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY THIRD LINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY THIRD LINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY THIRD LINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY THIRD LINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY THIRD LINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DOSAGE STRENGTH, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY HIGH DOSE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY HIGH DOSE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY HIGH DOSE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY HIGH DOSE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY HIGH DOSE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY HIGH DOSE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY LOW DOSE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY LOW DOSE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY LOW DOSE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY LOW DOSE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY LOW DOSE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY LOW DOSE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY STANDARD DOSE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY STANDARD DOSE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY STANDARD DOSE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY STANDARD DOSE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY STANDARD DOSE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY STANDARD DOSE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. AMERICAS PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 172. AMERICAS PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 173. AMERICAS PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2024 (USD MILLION)
  • TABLE 174. AMERICAS PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2025-2032 (USD MILLION)
  • TABLE 175. AMERICAS PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COMPLEMENT INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 176. AMERICAS PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COMPLEMENT INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 177. AMERICAS PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY GENE THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 178. AMERICAS PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY GENE THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 179. AMERICAS PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 180. AMERICAS PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 181. AMERICAS PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ADMINISTRATION FREQUENCY, 2018-2024 (USD MILLION)
  • TABLE 182. AMERICAS PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ADMINISTRATION FREQUENCY, 2025-2032 (USD MILLION)
  • TABLE 183. AMERICAS PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 184. AMERICAS PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 185. AMERICAS PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 186. AMERICAS PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 187. AMERICAS PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 188. AMERICAS PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 189. AMERICAS PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
  • TABLE 190. AMERICAS PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2025-2032 (USD MILLION)
  • TABLE 191. AMERICAS PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
  • TABLE 192. AMERICAS PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DOSAGE STRENGTH, 2025-2032 (USD MILLION)
  • TABLE 193. NORTH AMERICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. NORTH AMERICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. NORTH AMERICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2024 (USD MILLION)
  • TABLE 196. NORTH AMERICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2025-2032 (USD MILLION)
  • TABLE 197. NORTH AMERICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COMPLEMENT INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 198. NORTH AMERICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COMPLEMENT INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 199. NORTH AMERICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY GENE THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 200. NORTH AMERICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY GENE THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 201. NORTH AMERICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 202. NORTH AMERICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 203. NORTH AMERICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ADMINISTRATION FREQUENCY, 2018-2024 (USD MILLION)
  • TABLE 204. NORTH AMERICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ADMINISTRATION FREQUENCY, 2025-2032 (USD MILLION)
  • TABLE 205. NORTH AMERICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 206. NORTH AMERICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 207. NORTH AMERICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 208. NORTH AMERICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 209. NORTH AMERICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 210. NORTH AMERICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 211. NORTH AMERICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
  • TABLE 212. NORTH AMERICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2025-2032 (USD MILLION)
  • TABLE 213. NORTH AMERICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
  • TABLE 214. NORTH AMERICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DOSAGE STRENGTH, 2025-2032 (USD MILLION)
  • TABLE 215. LATIN AMERICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. LATIN AMERICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. LATIN AMERICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2024 (USD MILLION)
  • TABLE 218. LATIN AMERICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2025-2032 (USD MILLION)
  • TABLE 219. LATIN AMERICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COMPLEMENT INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 220. LATIN AMERICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COMPLEMENT INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 221. LATIN AMERICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY GENE THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 222. LATIN AMERICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY GENE THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 223. LATIN AMERICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 224. LATIN AMERICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 225. LATIN AMERICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ADMINISTRATION FREQUENCY, 2018-2024 (USD MILLION)
  • TABLE 226. LATIN AMERICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ADMINISTRATION FREQUENCY, 2025-2032 (USD MILLION)
  • TABLE 227. LATIN AMERICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 228. LATIN AMERICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 229. LATIN AMERICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 230. LATIN AMERICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 231. LATIN AMERICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 232. LATIN AMERICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 233. LATIN AMERICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
  • TABLE 234. LATIN AMERICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2025-2032 (USD MILLION)
  • TABLE 235. LATIN AMERICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
  • TABLE 236. LATIN AMERICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DOSAGE STRENGTH, 2025-2032 (USD MILLION)
  • TABLE 237. EUROPE, MIDDLE EAST & AFRICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 238. EUROPE, MIDDLE EAST & AFRICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 239. EUROPE, MIDDLE EAST & AFRICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2018-2024 (USD MILLION)
  • TABLE 240. EUROPE, MIDDLE EAST & AFRICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY TREATMENT CLASS, 2025-2032 (USD MILLION)
  • TABLE 241. EUROPE, MIDDLE EAST & AFRICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COMPLEMENT INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 242. EUROPE, MIDDLE EAST & AFRICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY COMPLEMENT INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 243. EUROPE, MIDDLE EAST & AFRICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY GENE THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 244. EUROPE, MIDDLE EAST & AFRICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY GENE THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 245. EUROPE, MIDDLE EAST & AFRICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 246. EUROPE, MIDDLE EAST & AFRICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY SUPPORTIVE THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 247. EUROPE, MIDDLE EAST & AFRICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ADMINISTRATION FREQUENCY, 2018-2024 (USD MILLION)
  • TABLE 248. EUROPE, MIDDLE EAST & AFRICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY ADMINISTRATION FREQUENCY, 2025-2032 (USD MILLION)
  • TABLE 249. EUROPE, MIDDLE EAST & AFRICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 250. EUROPE, MIDDLE EAST & AFRICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 251. EUROPE, MIDDLE EAST & AFRICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 252. EUROPE, MIDDLE EAST & AFRICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE, BY END USER